Literature DB >> 16140436

Enhancement of immune responses to an HBV DNA vaccine by electroporation.

A Luxembourg1, D Hannaman, B Ellefsen, G Nakamura, R Bernard.   

Abstract

These studies document the ability of electroporation (EP)-based DNA vaccination to induce multi-specific CTL responses to hepatitis B virus (HBV) DNA vaccination in normal mice and marked immune responses to multivalent HBV DNA immunization in larger animal species. These results suggest that electroporation-mediated HBV DNA vaccination is worth pursuing as a treatment for chronic HBV infection.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16140436     DOI： 10.1016/j.vaccine.2005.08.014

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  35 in total

1.  DNA vaccine: a promising new approach for chronic hepatitis B therapy.

Authors:  Lucyna Cova
Journal:  Future Virol       Date:  2007-09       Impact factor: 1.831

2.  DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells.

Authors:  Lara Vojnov; Alexander T Bean; Eric J Peterson; Maria J Chiuchiolo; Jonah B Sacha; Ferencz S Denes; Matyas Sandor; Deborah H Fuller; James T Fuller; Christopher L Parks; Adrian B McDermott; Nancy A Wilson; David I Watkins
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

3.  Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation.

Authors:  Ralph LeBlanc; Yessika Vasquez; Drew Hannaman; Nirbhay Kumar
Journal:  Vaccine       Date:  2007-11-20       Impact factor: 3.641

4.  The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells.

Authors:  Godwin Nchinda; Janelle Kuroiwa; Margarita Oks; Christine Trumpfheller; Chae Gyu Park; Yaoxing Huang; Drew Hannaman; Sarah J Schlesinger; Olga Mizenina; Michel C Nussenzweig; Klaus Uberla; Ralph M Steinman
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

5.  Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation.

Authors:  Chae Young Kim; Eun Sung Kang; Seon Beom Kim; Han Eol Kim; Jae Hoon Choi; Dong Sop Lee; Se Jin Im; Se Hwan Yang; Young Chul Sung; Byong Moon Kim; Byung Gee Kim
Journal:  Exp Mol Med       Date:  2008-12-31       Impact factor: 8.718

6.  Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.

Authors:  Xiaohong Jiang; Tim J Dalebout; Igor S Lukashevich; Peter J Bredenbeek; David Franco
Journal:  J Gen Virol       Date:  2014-12-16       Impact factor: 3.891

7.  Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes.

Authors:  Zahra Heidari; Jaspreet S Arora; Dibyadyuti Datta; Vijay T John; Nirbhay Kumar; Geetha P Bansal
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

8.  Electroporation-mediated gene delivery.

Authors:  Jennifer L Young; David A Dean
Journal:  Adv Genet       Date:  2014-12-11       Impact factor: 1.944

9.  Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.

Authors:  Tinashe B Ruwona; Erick Giang; Travis Nieusma; Mansun Law
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

10.  Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.

Authors:  Simon R Best; Shiwen Peng; Chi-Mou Juang; Chien-Fu Hung; Drew Hannaman; John R Saunders; T-C Wu; Sara I Pai
Journal:  Vaccine       Date:  2009-07-19       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.